Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodies.
Identifieur interne : 002555 ( Main/Merge ); précédent : 002554; suivant : 002556Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodies.
Auteurs : Lanying Du [États-Unis] ; Shibo Jiang [États-Unis]Source :
- Future virology [ 1746-0794 ] ; 2010.
Abstract
Evaluation of: Coughlin MM, Babcook J, Prabhakar BS: Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. Virology 394(1), 39-46 (2009). This work discusses passive immunotherapy based on neutralizing human monoclonal antibodies (mAbs) with different mechanisms of action. The authors have demonstrated that combining such mAbs, which target distinct epitopes, may greatly increase inhibition of virus infection and suppress the generation of neutralization escape mutants. The inhibition of human mAbs to SARS-coronavirus (CoV) may also act through different mechanisms of action, depending on their target epitopes or regions. Therefore, this approach could provide fast and effective prophylaxis and treatment of SARS-CoV infection during a SARS outbreak. Specifically, Coughlin et al. have indicated that most of the tested anti-S1 mAbs recognized epitopes within the receptor-binding domain and blocked virus attachment to its cellular receptor. These findings could provide a further step in understanding the mechanism of these mAbs in the prevention of SARS-CoV infection, as well as an insight into the design and development of novel therapeutic treatments.
DOI: 10.2217/fvl.09.78
PubMed: 32201501
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001743
- to stream PubMed, to step Curation: 001743
- to stream PubMed, to step Checkpoint: 001651
- to stream Ncbi, to step Merge: 003479
- to stream Ncbi, to step Curation: 003479
- to stream Ncbi, to step Checkpoint: 003479
Links to Exploration step
pubmed:32201501Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodies.</title><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name><affiliation wicri:level="2"><nlm:affiliation>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA. ldu@nybloodcenter.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="2"><nlm:affiliation>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA. Tel.: +1 212 570 3058; ; sjiang@nybloodcenter.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:32201501</idno><idno type="pmid">32201501</idno><idno type="doi">10.2217/fvl.09.78</idno><idno type="wicri:Area/PubMed/Corpus">001743</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001743</idno><idno type="wicri:Area/PubMed/Curation">001743</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001743</idno><idno type="wicri:Area/PubMed/Checkpoint">001651</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001651</idno><idno type="wicri:Area/Ncbi/Merge">003479</idno><idno type="wicri:Area/Ncbi/Curation">003479</idno><idno type="wicri:Area/Ncbi/Checkpoint">003479</idno><idno type="wicri:doubleKey">1746-0794:2010:Du L:immunotherapy:of:sars</idno><idno type="wicri:Area/Main/Merge">002555</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodies.</title><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name><affiliation wicri:level="2"><nlm:affiliation>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA. ldu@nybloodcenter.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="2"><nlm:affiliation>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA. Tel.: +1 212 570 3058; ; sjiang@nybloodcenter.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j">Future virology</title><idno type="ISSN">1746-0794</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Evaluation of: Coughlin MM, Babcook J, Prabhakar BS: Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. <i>Virology</i> 394(1), 39-46 (2009).</b> This work discusses passive immunotherapy based on neutralizing human monoclonal antibodies (mAbs) with different mechanisms of action. The authors have demonstrated that combining such mAbs, which target distinct epitopes, may greatly increase inhibition of virus infection and suppress the generation of neutralization escape mutants. The inhibition of human mAbs to SARS-coronavirus (CoV) may also act through different mechanisms of action, depending on their target epitopes or regions. Therefore, this approach could provide fast and effective prophylaxis and treatment of SARS-CoV infection during a SARS outbreak. Specifically, Coughlin <i>et al.</i> have indicated that most of the tested anti-S1 mAbs recognized epitopes within the receptor-binding domain and blocked virus attachment to its cellular receptor. These findings could provide a further step in understanding the mechanism of these mAbs in the prevention of SARS-CoV infection, as well as an insight into the design and development of novel therapeutic treatments.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002555 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002555 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:32201501
|texte= Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:32201501" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |